---
title: "Sun Pharma cleared to sell generic Wegovy, intensifies India's obesity‑drug race"
description: "Sun Pharmaceutical Industries has received regulatory approval to manufacture and sell semaglutide, the generic version of Wegovy, in India. The drug will be marketed as Noveltreat for weight loss aft"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/273468156.md"
published_at: "2026-01-23T05:38:49.000Z"
---

# Sun Pharma cleared to sell generic Wegovy, intensifies India's obesity‑drug race

> Sun Pharmaceutical Industries has received regulatory approval to manufacture and sell semaglutide, the generic version of Wegovy, in India. The drug will be marketed as Noveltreat for weight loss after the patent expires in March. This move allows Indian generic drugmakers to enter a lucrative market projected to reach $150 billion globally. Sun Pharma is the second Indian company to gain approval for generic semaglutide, following Dr Reddy’s Laboratories. The company also plans to launch a generic version of Ozempic under the name Sematrinity.

By Kashish Tandon and Rishika Sadam

Jan 23 (Reuters) - Sun Pharmaceutical Industries (SUN.NS) , India’s top drugmaker by revenue, said on Friday it has received a regulatory nod to manufacture and sell semaglutide, the generic version of blockbuster weight-loss drug Wegovy, in the populous nation.

The drugmaker plans to launch generic semaglutide, the active ingredient in Novo Nordisk’s (NOVOb.CO) Wegovy and its blockbuster diabetes drug Ozempic, under the brand name Noveltreat for weight loss once the semaglutide patent expires in March.

The upcoming patent expiry for semaglutide opens the door for Indian generic drugmakers to enter the weight-loss market with cheaper versions of both Wegovy and Ozempic.

The entry of generic drugmakers into the lucrative market, projected to reach $150 billion globally by the end of the decade, is expected to pressure sales of branded drugs, as copycat versions typically launch at steep discounts.

Last year, U.S. drugmaker Eli Lilly (LLY.N) launched Mounjaro in India, while Danish drugmaker Novo introduced Wegovy and Ozempic. Sales of the drugs doubled shortly after launch.

Sun Pharma is now the second Indian company to secure regulatory approval for generic semaglutide, following Dr Reddy’s Laboratories (REDY.NS) , which earlier this week announced approval to manufacture and sell the generic version of Ozempic.

Semaglutide belongs to a class of therapies that help control blood sugar and slow digestion.

“The generic players will come in with lower prices and expand the number of people they can reach out to given their aggressive marketing strategy,” said Vishal Manchanda, an analyst with Systematix Institutional Equities.

Sun Pharma said Noveltreat will be available in the same dose strengths as Wegovy.

The company also plans to launch a generic version of Ozempic under the brand name Sematrinity. Sun Pharma received regulatory approval for Sematrinity in December.

Ozempic, though mainly approved for type 2 diabetes, is used off-label for weight loss due to its appetite-suppressing effects.

### Related Stocks

- [RDY.US - Dr Reddys Laboratories](https://longbridge.com/en/quote/RDY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Indian drugmaker Dr Reddy's gearing up for March debut of generic semaglutide Obeda, sources say | Indian drugmaker Dr Reddy's Laboratories is set to launch its generic semaglutide injection, branded as Obeda, in March  | [Link](https://longbridge.com/en/news/276858725.md) |
| Novo Nordisk: Will Have Replacements for Ozempic and Wegovy Ready When Patents Expire - Berlingske | Danish pharmaceutical company Novo Nordisk plans to have replacement drugs ready for Ozempic and Wegovy when their paten | [Link](https://longbridge.com/en/news/276314777.md) |
| Novo Nordisk's CEO: We need to be aware that there is an abnormality with how the comparator drug has performed in the study | Novo Nordisk's CEO: We need to be aware that there is an abnormality with how the comparator drug has performed in the s | [Link](https://longbridge.com/en/news/276589591.md) |
| Novo Nordisk - New, Lower List Price of $675 per Month Across Wegovy(®), Ozempic(®), and Rybelsus(®), Effective January 1, 2027 | Novo Nordisk - New, Lower List Price of $675 per Month Across Wegovy(®), Ozempic(®), and Rybelsus(®), Effective January  | [Link](https://longbridge.com/en/news/276739132.md) |
| Assessing Novo Nordisk (NYSE:NVO) Valuation After Share Price Pullback And GLP 1 Growth Prospects | Novo Nordisk (NYSE:NVO) has experienced a 24% decline in share price over the past month, with a total return of 45% dow | [Link](https://longbridge.com/en/news/276640505.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.